EXACT SCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.51 USD | -1.18% |
|
-13.79% | -27.67% |
Presentation Operator MessageOperator (Operator)Good evening. My name is Colby and I will be y...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
53.51
USD
Average target price
86.59
USD
Spread / Average Target
+61.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.67% | 9.87B | |
| +34.87% | 3.07B | |
| -17.30% | 2.73B | |
| -11.15% | 2.24B | |
| -22.32% | 1.63B | |
| +23.58% | 771M | |
| -1.31% | 760M | |
| -28.57% | 516M | |
| +5.37% | 310M | |
| +12.46% | 219M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Transcript : Exact Sciences Corporation, Q3 2022 Earnings Call, Nov 03, 2022